Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

3F1Q

Human dihydroorotate dehydrogenase in complex with a leflunomide derivative inhibitor 1

Summary for 3F1Q
Entry DOI10.2210/pdb3f1q/pdb
DescriptorDihydroorotate dehydrogenase, FLAVIN MONONUCLEOTIDE, OROTIC ACID, ... (7 entities in total)
Functional Keywordsdihydroorotate dehydrogenase, leflunomide, fad, flavoprotein, membrane, mitochondrion, mitochondrion inner membrane, oxidoreductase, pyrimidine biosynthesis, transit peptide
Biological sourceHomo sapiens (human)
Cellular locationMitochondrion inner membrane; Single-pass membrane protein: Q02127
Total number of polymer chains1
Total formula weight40963.45
Authors
Heikkila, T.,Davies, M.,McConkey, G.A.,Fishwick, C.W.G.,Parsons, M.R.,Johnson, A.P. (deposition date: 2008-10-28, release date: 2009-06-09, Last modification date: 2023-11-01)
Primary citationDavies, M.,Heikkila, T.,McConkey, G.A.,Fishwick, C.W.G.,Parsons, M.R.,Johnson, A.P.
Structure-based design, synthesis, and characterization of inhibitors of human and Plasmodium falciparum dihydroorotate dehydrogenases
J.Med.Chem., 52:2683-2693, 2009
Cited by
PubMed Abstract: Pyrimidine biosynthesis is an attractive drug target in a variety of organisms, including humans and the malaria parasite Plasmodium falciparum. Dihydroorotate dehydrogenase, an enzyme catalyzing the only redox reaction of the pyrimidine biosynthesis pathway, is a well-characterized target for chemotherapeutical intervention. In this study, we have applied SPROUT-LeadOpt, a software package for structure-based drug discovery and lead optimization, to improve the binding of the active metabolite of the anti-inflammatory drug leflunomide to the target cavities of the P. falciparum and human dihydroorotate dehydrogenases. Following synthesis of a library of compounds based upon the SPROUT-optimized molecular scaffolds, a series of inhibitors generally showing good inhibitory activity was obtained, in keeping with the SPROUT-LeadOpt predictions. Furthermore, cocrystal structures of five of these SPROUT-designed inhibitors bound in the ubiquinone binding cavity of the human dihydroorotate dehydrogenase are also analyzed.
PubMed: 19351152
DOI: 10.1021/jm800963t
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2 Å)
Structure validation

226707

數據於2024-10-30公開中

PDB statisticsPDBj update infoContact PDBjnumon